5 Key Takeaways

• 1

  The NEW DAY trial compares fluocinolone acetonide implant with aflibercept in patients with retinal vascular disease.

• 2

  Fluocinolone showed fewer required injections, but this did not reach statistical significance.

• 3

  OCT thickness remained stable with fluocinolone, while anti-VEGF injections caused fluctuations.

• 4

  Intraocular pressure (IOP) monitoring revealed that significant optic nerve damage was not associated with IOP increases.

• 5

  Only 1.9% of participants required incisional glaucoma surgery during the trial.